Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Secukinumab Therapy for Netherton Syndrome.

JAMA dermatology - 1 Aug 2020

Luchsinger Isabelle, Knöpfel Nicole, Theiler Martin, Bonnet des Claustres Mathilde, Barbieux Claire, Schwieger-Briel Agnes, Brunner Corinne, Donghi Davide, Buettcher Michael, Meier-Schiesser Barbara, Hovnanian Alain, Weibel Lisa

Abstract excerpt

Importance: Netherton syndrome (NS) is a rare, severe genetic disorder of cornification with high morbidity. Treatment for NS has been notoriously difficult. Recent studies showed an upregulated helper T cell (TH) 17/interleukin 23 (IL-23) pathway in NS, suggesting the possibility of treatment strategies that target IL-17. Objective: To evaluate the clinical response of NS to treatment with the IL-17 antagonist...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Dermatologic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interleukin-17

Share to Pruritus

Share to Quality of Life

Share to Severity of Illness Index

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 32459284
DOI: 10.1001/jamadermatol.2020.1019
PMCID: PMC7254452

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Secukinumab Therapy for Netherton Syndrome.PMID 32459284Read ↗

Ustekinumab therapy for Netherton syndrome.Semantic proximity Read ↗

Successful use of secukinumab in Netherton syndromeSemantic proximity Read ↗

Segmental stiff skin syndrome: a novel case with an interleukin-17C mutation successfully treated with secukinumab.Semantic proximity Read ↗

The Clinical Phenotypes and Therapeutic Strategies for Stiff Skin Syndrome: A Case Series with Literature ReviewSemantic proximity Read ↗

Netherton Syndrome -- a therapeutic challenge in childhoodSemantic proximity Read ↗

SPINK5 Variants Drive Clinical Variability in Netherton Syndrome Through Th2/Th17 Skewing and Influence Therapeutic Outcomes.Semantic proximity Read ↗

Immunological phenotype and skin modeling of Netherton syndrome.Semantic proximity Read ↗

Successful treatment of Netherton syndrome with dupilumab: A case report and review of the literature.Semantic proximity Read ↗

Impetigo herpetiformis with IL-36RN mutation successfully treated with secukinumab.Semantic proximity Read ↗

Transcriptomic profiling of plaque psoriasis and cutaneous T cell subsets during treatment with secukinumabSemantic proximity Read ↗

ANCA-associated vasculitis following secukinumab treatment for psoriasis: Expanding the Spectrum of IL-17A Inhibitor-Related Autoimmunity— A Case ReportSemantic proximity Read ↗

Effect of secukinumab on inflammatory linear verrucous epidermal naevus with a somatic mutation in CARD14.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.